Statistical issues in drug development
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Kaituhi rangatōpū: | |
| Hōputu: | Tāhiko īPukapuka |
| Reo: | Ingarihi |
| I whakaputaina: |
Chichester, England ; Hoboken, NJ :
John Wiley & Sons,
c2007.
|
| Putanga: | 2nd ed. |
| Rangatū: | Statistics in practice.
|
| Ngā marau: | |
| Urunga tuihono: | An electronic book accessible through the World Wide Web; click to view |
| Ngā Tūtohu: |
Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
Rārangi ihirangi:
- A brief and superficial history of statistics for drug developers
- Design and interpretation of clinical trials as seen by a statistician
- Probability, Bayes, P-values, tests of hypotheses, and confidence intervals
- The work of the pharmaceutical statistician
- Allocating treatments to patients in clinical trials
- Baselines and covariate information
- The measurement of treatment effects
- Demographic subgroups : representation and analysis
- Multiplicity
- Intention to treat, missing data and related matters
- One-sided and two-sided tests and other issues to do with significance and P-values
- Determining the sample size
- Multicentre trials
- Active control equivalence studies
- Meta-analysis
- Cross-over trials
- n-of-1 trials
- Sequential trials
- Dose-finding
- Concerning pharmacokinetics and pharmacodynamics
- Bioequivalence studies
- Safety data, harms, drug monitoring, and pharmaco-epidemiology
- Pharmaco-economics and portfolio management
- Concerning pharmacogenetics, pharmacogenomics, and related matters.